InfliximabDrug ineffective and off-label use: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2025年 / 2051卷 / 1期

关键词：

D O I：

10.1007/s40278-025-79667-7

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：147 / 147

相关论文

共 50 条

[41] DexamethasoneMucormycosis following off-label use: case report
Reactions Weekly, 2023, 1956 (1) : 181 - 181
[42] SintilimabFasciitis following off-label use: case report
Reactions Weekly, 2021, 1884 (1) : 391 - 391
[43] HydroxychloroquineEosinophilia following off-label use: case report
Reactions Weekly, 2021, 1867 (1) : 204 - 204
[44] GlibenclamideHypoglycaemia following an off-label use : case report
Reactions Weekly, 2021, 1866 (1) : 190 - 190
[45] HydroxychloroquineHaemolysis following off-label use: case report
Reactions Weekly, 2021, 1836 (1) : 376 - 376
[46] CannabidiolLiver disorder and off-label use: case report
Reactions Weekly, 2021, 1882 (1) : 116 - 116
[47] Infliximab/nivolumabPsoriasis and off-label use: case report
Reactions Weekly, 2023, 1984 (1) : 272 - 272
[48] Lapatinib/nivolumabFatigue and off-label use: case report
Reactions Weekly, 2018, 1722 (1) : 200 - 200
[49] SpironolactoneHyperkalaemia secondary to off-label use: case report
Reactions Weekly, 2021, 1836 (1) : 710 - 710
[50] ItraconazoleLack of efficacy and off-label use: case report
Reactions Weekly, 2022, 1911 (1) : 254 - 254

← 1 2 3 4 5 →